The Company, the FDA has permission to submit the PMA Aorfix in a series of 6 modules. The first three of these modules to biological testing, non-clinical laboratory studies, and sterilization and packaging have already been reviewed and accepted by the FDA. The fourth module on the test bench and shelf life was presented in November and the penultimate module production has been filed. The last module of of the clinical data is expected to be filed in the first half of 2011.

Please provide the link to the published ARTICLE IN ONLINE versions of your REPORT:CONTACT:Maya Ponte University of California San Francisco, Anthropology, History and Social Medicine 1446 Rhode Iceland St. San Francisco, CA United 94107 States of America###Social medicine in the 21stof 2011. Fifth PMA to FDALombard Medical Technologies PLC , a medical device company in solutions for the $ 1 billion abdominal aortic aneurysm repair market is concentrated, has announced that the fifth of six submitted Pre – Market Approval – modules. Required for U.S. Approval of Aorfix by the U.S. Food and Drug Administration .In carrying out its studies investigates one hundred and four consecutive patients with Scheopf 64-slice cardiac CT on the Medical University of South Carolina. Krebs patients were male. With a mean age of 59 years and the mean weight of 202 lbs The research team converted to organ radiation doses to risk groups with a a previously published and validates operation. Outpatient cancers risks of have adjusted in the light patient sex, age and weight, the latter being an oft neglected factor radiation risk.

In previously published studies include variety researchers risk of cancer after radiation exposure with CT of cardiovascular diseases is approximately 1 in 114, but your new study suggests that the risk of is 1 in 1000. Joseph Schoepf, and colleague from MUSC, thus prior trials in which lifetime risks of from cancer caused by rays in the cardiac CT be based based on unreliable model out of patients who have undergoing CT for cardiovascular disease..